Amgen’s shares approached a 52-week peak of $447.03 on Thursday, trading at $441.56, after a 55.4% gain over the past year. The stock remains 1.9% below its consensus fair value estimate of $450.00, though analyst targets imply limited near-term upside at a median level 10.8% below current prices.
The company’s valuation metrics reflect its growth trajectory, with a trailing price-to-earnings ratio of 27.4x and a forward P/E of 19.1x. Enterprise value to EBITDA stands at 16.0x, while the dividend yield is 2.3%. Amgen’s leverage remains elevated, with a debt-to-equity ratio of 490.3% following the $3.7 billion acquisition of Horizon Therapeutics.
Revenue has expanded from $25.98 billion in fiscal 2021 to an estimated $36.75 billion in 2025, a 41.4% increase over four years. EBITDA grew from $12.55 billion to $16.62 billion, and free cash flow has averaged roughly $8.6 billion annually over the past five years.
Technical indicators suggest continued bullish momentum, with a "Strong Buy" rating across all timeframes. The weekly Relative Strength Index (RSI) stands at 72.8, while the Stochastic RSI is at 93.5, indicating overbought conditions. Daily support levels are identified at $436.71 and $430.57, with a potential pullback zone between $426 and $430. Resistance levels sit at $447.28 and $451.71. The daily MACD reading of 13.43 reinforces accelerating upward momentum.
Pipeline developments include the Phase 3 CROSSING trial for Tezspire, which met both co-primary endpoints in eosinophilic esophagitis on August 26, 2026. The drug, developed in partnership with AstraZeneca, targets a U.S. patient population exceeding 470,000, with roughly half inadequately controlled. Amgen is also advancing MariTide, a candidate in the competitive GLP-1 obesity and diabetes market.
Regulatory challenges persist, including the FTC’s antitrust challenge against the Enbrel patent acquisition and the suspension of Tavneos in the UK following the EU’s revocation of its approval due to unreliable trial data. Piper Sandler recently raised its price target to $457, reflecting cautious optimism despite near-term headwinds.
